What I find interesting is that B already was given QIDP designation which I believe makes B applicable to the pathogens likely to be part of the REVAMP incentive program (there is a CDC list). Can you imagine Abbvie being interested in moving B forward since they could potentially get an extra year of exclusivity on Humira which generates over $15B per year? So...why not just purchase the B platform with the promise of B-OM and B-UP and with the potential for B to be worth another year of Humira revenue?